[go: up one dir, main page]

MA45126A - Formulation pharmaceutique antifongique - Google Patents

Formulation pharmaceutique antifongique

Info

Publication number
MA45126A
MA45126A MA045126A MA45126A MA45126A MA 45126 A MA45126 A MA 45126A MA 045126 A MA045126 A MA 045126A MA 45126 A MA45126 A MA 45126A MA 45126 A MA45126 A MA 45126A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulation
antifungal pharmaceutical
antifungal
formulation
pharmaceutical
Prior art date
Application number
MA045126A
Other languages
English (en)
Inventor
Derek Law
Graham Edward Morris Sibley
Original Assignee
F2G Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F2G Ltd filed Critical F2G Ltd
Publication of MA45126A publication Critical patent/MA45126A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045126A 2016-05-25 2017-05-25 Formulation pharmaceutique antifongique MA45126A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MA45126A true MA45126A (fr) 2021-04-14

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045126A MA45126A (fr) 2016-05-25 2017-05-25 Formulation pharmaceutique antifongique

Country Status (26)

Country Link
US (2) US10973821B2 (fr)
EP (1) EP3463365B1 (fr)
JP (1) JP7141108B2 (fr)
KR (1) KR102464150B1 (fr)
CN (1) CN109982704B (fr)
AU (1) AU2017270942B2 (fr)
CA (1) CA3024771A1 (fr)
CY (1) CY1124733T1 (fr)
DK (1) DK3463365T3 (fr)
ES (1) ES2888951T3 (fr)
GB (1) GB201609222D0 (fr)
HR (1) HRP20211795T1 (fr)
HU (1) HUE056129T2 (fr)
IL (1) IL263167B (fr)
LT (1) LT3463365T (fr)
MA (1) MA45126A (fr)
MX (1) MX2018014232A (fr)
MY (1) MY197663A (fr)
NZ (1) NZ748394A (fr)
PL (1) PL3463365T3 (fr)
PT (1) PT3463365T (fr)
RU (1) RU2760681C2 (fr)
SG (1) SG11201810323RA (fr)
SI (1) SI3463365T1 (fr)
WO (1) WO2017203270A1 (fr)
ZA (1) ZA201807851B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
GB1051723A (fr) 1962-04-27
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (fr) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
BR9508298A (pt) 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
WO1996033973A1 (fr) 1995-04-28 1996-10-31 Banyu Pharmaceutical Co., Ltd. Derives disubstitues en position 1,4 de piperidine
EP0747756B1 (fr) 1995-06-06 2000-05-24 Agfa-Gevaert N.V. Matériaux photographiques
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
DE69819721T2 (de) 1997-06-13 2004-09-23 Cydex Inc., Overland Park Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
SK18312000A3 (sk) 1998-06-03 2001-06-11 Gpi Nil Holdings, Inc. Aza-heterocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
DE60039802D1 (de) 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
DE60001734T2 (de) 1999-05-04 2004-02-05 Janssen Pharmaceutica N.V. Antimykotische ether
WO2001008572A1 (fr) 1999-07-30 2001-02-08 Norbert Heske Systeme de canule permettant l'introduction d'instruments endoscopiques dans un corps humain ou animal
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
WO2002098876A1 (fr) 2001-06-06 2002-12-12 Vertex Pharmaceuticals Incorporated Inhibiteurs de cak et leurs utilisations
PL214669B1 (pl) 2001-06-20 2013-08-30 Daiichi Sankyo Company Pochodne diaminy, kompozycja je zawierajaca oraz ich zastosowanie
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
WO2003072028A2 (fr) 2002-02-23 2003-09-04 Bristol-Myers Squibb Company Procede de traitement de l'infection par le vih consistant a eviter toute interaction du cd4 et du gp120
KR20060021278A (ko) 2002-08-15 2006-03-07 윤킹 리우 고체 나노미터 의약 및 이의 제조방법
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
TW200505915A (en) 2003-03-13 2005-02-16 Synta Pharmaceuticals Corp Fused pyrrole compounds
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06004438A (es) 2003-10-24 2006-06-20 Schering Ag Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
ATE409462T1 (de) 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
EP2548894A1 (fr) 2005-02-03 2013-01-23 Bend Research, Inc. Compositions pharmaceutiques à éfficacité améliorée
WO2006105289A1 (fr) 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Composes de pyrazole bicycliques utilises comme agents antibacteriens
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
JP5172661B2 (ja) 2005-05-18 2013-03-27 エフ２ジー リミテッド 抗真菌剤
EP1907347A2 (fr) 2005-07-12 2008-04-09 Arcadia Pharmaceuticals Inc. Composes presentant une activite au niveau des recepteurs de l'acide retinoique
WO2007015866A2 (fr) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires
KR20090025187A (ko) 2006-03-20 2009-03-10 버텍스 파마슈티칼스 인코포레이티드 의약 조성물
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009130481A1 (fr) 2008-04-24 2009-10-29 F2G Ltd Agents antifongiques à base de pyrrole
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CA2760305A1 (fr) 2009-04-28 2010-11-04 Boehringer Ingelheim International Gmbh Traitement ex vivo de troubles immunologiques par des inhibiteurs de pkc-theta
WO2011159626A1 (fr) 2010-06-14 2011-12-22 Bend Research, Inc. Acétosuccinate d'hydroxypropylméthylcellulose avec substitution acétate et succinate améliorée
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012060448A1 (fr) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition pharmaceutique combinée en tant qu'agent antifongique
EP2529731A1 (fr) 2011-06-01 2012-12-05 Nitto Denko Corporation Préparation de particules et son procédé de production
KR101922752B1 (ko) 2011-11-29 2018-11-27 주록스 피티와이 리미티드 사이클로덱스트린 및 소수성 약물을 포함하는 주사용 약제학적 조성물을 보존하는 방법
KR20140146181A (ko) 2012-04-11 2014-12-24 다우 글로벌 테크놀로지스 엘엘씨 특정 치환체 분포를 갖는 에스테르화된 셀룰로즈 에테르
BR112015002055A2 (pt) 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
JP6224711B2 (ja) 2012-08-24 2017-11-01 ダウ グローバル テクノロジーズ エルエルシー 部分架橋結合型エステル化セルロースエーテル
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
WO2015007759A1 (fr) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Composition pharmaceutique aqueuse liquide contenant des dérivés de cyclodextrine éthérifiée
WO2015007760A1 (fr) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Composition pharmaceutique aqueuse liquide contenant des dérivés de cyclodextrine éthérifiés conservés
US20160303102A1 (en) 2013-12-05 2016-10-20 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
KR102550341B1 (ko) * 2014-11-21 2023-06-30 에프2지 리미티드 항진균제
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Also Published As

Publication number Publication date
EP3463365A1 (fr) 2019-04-10
ZA201807851B (en) 2022-04-28
WO2017203270A1 (fr) 2017-11-30
LT3463365T (lt) 2021-11-10
HRP20211795T1 (hr) 2022-03-18
NZ748394A (en) 2024-11-29
AU2017270942A1 (en) 2018-12-06
EP3463365B1 (fr) 2021-08-25
BR112018074162A2 (pt) 2019-03-06
DK3463365T3 (da) 2021-09-20
CY1124733T1 (el) 2022-07-22
JP7141108B2 (ja) 2022-09-22
CA3024771A1 (fr) 2017-11-30
US20210186967A1 (en) 2021-06-24
RU2018142381A (ru) 2020-06-25
IL263167B (en) 2022-07-01
MX2018014232A (es) 2019-03-28
SI3463365T1 (sl) 2022-01-31
RU2018142381A3 (fr) 2020-09-30
IL263167A (en) 2018-12-31
US10973821B2 (en) 2021-04-13
RU2760681C2 (ru) 2021-11-29
CN109982704A (zh) 2019-07-05
GB201609222D0 (en) 2016-07-06
MY197663A (en) 2023-06-30
KR20190013865A (ko) 2019-02-11
US20190328737A1 (en) 2019-10-31
KR102464150B1 (ko) 2022-11-07
SG11201810323RA (en) 2018-12-28
HUE056129T2 (hu) 2022-01-28
CN109982704B (zh) 2023-10-24
PT3463365T (pt) 2021-09-28
AU2017270942B2 (en) 2022-07-21
ES2888951T3 (es) 2022-01-10
PL3463365T3 (pl) 2022-01-10
JP2019516765A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
SI3529248T1 (sl) Farmacevtske spojine
EP3454899C0 (fr) Composition pharmaceutique
EP3325016C0 (fr) Composition pharmaceutique comprenant un vecteur adrenoviral
MA46334A (fr) Composition pharmaceutique liquide
DK3479819T5 (da) Stabilt væskeformigt farmaceutisk præparat
MA43705A (fr) Formulation pharmaceutique
EP3476386C0 (fr) Composition pharmaceutique liquide
DK3634377T3 (da) Farmaceutisk formulering
DK3532029T3 (da) Flydende farmaceutisk sammensætning
LT3655038T (lt) Farmacinė kompozicija
EP3452075A4 (fr) Composition pharmaceutique ophtalmique
DK3529240T3 (da) Farmaceutiske forbindelser
EP3603642A4 (fr) Préparation pharmaceutique
DK3463345T3 (da) Farmaceutiske kombinationer
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
MA47516A (fr) Composition pharmaceutique
EP3437644A4 (fr) Médicament
EP3646866A4 (fr) Préparation pharmaceutique
EP3638322A4 (fr) Formulation de décontamination
DK3280447T3 (da) Farmaceutiske formuleringer
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
EP3383371A4 (fr) Formulation pharmaceutique
EP3527216A4 (fr) Médicament
EP3727485C0 (fr) Composition pharmaceutique
MA45126A (fr) Formulation pharmaceutique antifongique